53 Comparison of 3 neoadjuvant chemotherapy regimens for operable breast cancerCELL-CELL ADHESIONCELL MOTILITYTUMOR INVASIONTPAIn order to avoid modified radical mastectomy a neoadjuvant approach was adopted in our institute for non-inflammatory tumours. From 01/88 to 12/94,238 patients (pts) received...
As a low economic diagnostic model, low axillary lymph node sampling technology proved better in comparison to sentinel node biopsy [28, 29]. Lairson et al. performed CEA of breast cancer chemotherapy, comparing anthracycline-based regimens to non-anthracycline-based regimens. They found the ...
Chemotherapy medicines are used to kill cancer cells. You may receive one medicine or a combination of medicines. Inhibitor medicines may be given to help destroy the cancer cells. One medicine helps your immune system kill the cells. Another medicine makes the cells die by preventing them from...
All side effects were tolerable. CONCLUSION: CAF regimen was still a firstly selected regimen for the patients with ABC. 展开 关键词: Advanced breast cancer (ABC Chemotherapy Paclitaxel Adriamycin DOI: http://dx.doi.org/ 被引量: 7 年份: 2003 ...
To elucidate the effects of neoadjuvant chemotherapy (NAC), we conduct whole transcriptome profiling coupled with histopathology analyses of a longitudinal breast cancer cohort of 146 patients including 110 pairs of serial tumor biopsies collected before
Objective To evaluate the efficacy and toxicity of THP-containing regimen or ADM-containing regimen in the treatment of breast cancer after operation. Method Seventy-two cases were stageⅡ -Ⅲ breast cancer after operation. Forth-two cases were treated by THP-containing regimen for 6 cycles,and ...
Interventions The adjuvant chemotherapy regimen was selected by the treating physician. Main Outcomes and Measures Freedom from recurrence of breast cancer at a distant site, and freedom from recurrence, second primary cancer, and death (also known as invasive disease-free survival [IDFS]). Results ...
Results: The chemotherapy regimen used significantly influenced disease-free survival (p=0.02). The impact on relapse appeared comparable choosing either CMF scheme or anthracyclines. Whereas, taxane-containing regimens proved to be significantly protective against relapse (HR=0.33), by univariate Cox ...
any compensation. In the cohort of patients with sBBCs treated with NAT, regimens were as follows: neoadjuvant chemotherapy (n = 50, 46 of whom received anthracyclines/taxanes-based sequential regimen) or neoadjuvant endocrine therapy (NET,n = 20, 18 of whom received aromatase ...
Luminal B tumours are also associated with multicentricity and multifocality, skin and nipple-areolar involvement, and axillary disease (67), representing imaging evidence suggestive of aggressiveness of luminal B tumours in comparison to luminal A. HER2-positive breast cancer accounts for about 15%...